Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Status:
Completed
Trial end date:
2017-03-14
Target enrollment:
Participant gender:
Summary
2 Part Study: Part A will assess 3 different dosing levels of IV CR845 versus placebo in
patient on hemodialysis who have moderate-to-severe itching due to uremic pruritus. Patients
will receive either CR845 or placebo after each dialysis session for eight weeks. The safety
and efficacy of CR845 will be monitored throughout the study. A sub-group of patients will
also have pharmacokinetic assessments completed. Part B of the study will assess one dose of
IVCR845 versus placebo for 12 weeks in patients on hemodialysis who have moderate-to-severe
itching. The dose of CR845 used in Part B will be based on safety and efficacy found in Part
A.